Stay updated with breaking news from Aipsc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EF Hutton Acquisition Co. I reissued their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $16.00 price target on the stock. Other analysts also recently issued reports about the company. SVB Leerink reduced their price objective […]
HC Wainwright reaffirmed their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a research report report published on Thursday, Benzinga reports. They currently have a $17.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. Chardan Capital restated a buy rating and […]
HC Wainwright reaffirmed their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $17.00 price objective on the stock. Several other research firms have also recently commented on IPSC. Piper Sandler decreased their price target on shares of Century Therapeutics […]
HC Wainwright reaffirmed their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $17.00 price target on the stock. IPSC has been the topic of a number of other research reports. Bank of America dropped their price objective on […]
Century Therapeutics (NASDAQ:IPSC – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at EF Hutton Acquisition Co. I in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $16.00 target price on the stock. EF Hutton Acquisition Co. I’s target price points to a potential […]